Icon PLC - (ICLR) closed at $214.16 on October 28, 2026, up 17.0% from the previous close, on volume of 3,681,020 shares (30-day average 915,759).
Data as of October 28, 2026.
28-Oct-2026
Analysts Are Bullish on Top Healthcare Stocks: Icon (ICLR), Beam Therapeutics (BEAM)
TipRanks (Wed, 28-Oct 11:41 AM ET)
TipRanks (Wed, 28-Oct 9:40 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Wed, 28-Oct 7:00 AM ET)
ICON Restructures Debt, Expands Buybacks and Extends Option Plans
TipRanks (Tue, 27-Oct 5:31 PM ET)
ICON plc Posts Strong Q3 2026 Bookings, Refinances Debt With $2.15 Billion Bond
TipRanks (Tue, 27-Oct 5:19 PM ET)
Icon Non-GAAP EPS of $2.66 beats by $0.03, revenue of $2.02B beats by $10M
Seeking Alpha News (Tue, 27-Oct 4:52 PM ET)
ICON Reports Third Quarter 2026 Results
Business Wire (Tue, 27-Oct 4:43 PM ET)
Seeking Alpha News (Tue, 27-Oct 11:00 AM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 27-Oct 10:00 AM ET)
IQVIA gains as R&D Solutions drive Q3 beat
Seeking Alpha News (Tue, 27-Oct 8:48 AM ET)
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
Icon PLC - trades on the NASDAQ stock market under the symbol ICLR.
As of October 28, 2026, ICLR stock price climbed to $214.16 with 3,681,020 million shares trading.
ICLR has a beta of 1.04, meaning it tends to be more sensitive to market movements. ICLR has a correlation of 0.03 to the broad based SPY ETF.
ICLR has a market cap of $16.52 billion. This is considered a Large Cap stock.
Last quarter Icon PLC - reported $2 billion in Revenue and $2.66 earnings per share. This beat revenue expectation by $13 million and exceeded earnings estimates by $.08.
In the last 3 years, ICLR traded as high as $347.72 and as low as $66.57.
The top ETF exchange traded funds that ICLR belongs to (by Net Assets): SEQ, DFSV, DFAT, DFAS, PIEQ.
ICLR has outperformed the market in the last year with a price return of +17.7% while the SPY ETF gained +13.8%. ICLR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +26.9% and +30.3%, respectively, while the SPY returned +4.8% and -0.7%, respectively.
ICLR support price is $176.84 and resistance is $189.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICLR shares will trade within this expected range on the day.